The Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health and Family Welfare, organized a Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026 titled 'Strengthening Pharmaceutical Manufacturing through Pharmacopoeial Standards and Quality Compliance' in Haridwar on June 10, 2026. The event was conducted in collaboration with the Association of Devbhumi Pharma Industries (ADPI) and affiliated pharmaceutical manufacturing associations of Uttarakhand, with the objective of enhancing awareness on the provisions of IP 2026 and promoting quality compliance across the pharmaceutical manufacturing sector.
Uttarakhand was selected as the venue due to its status as one of India's leading pharmaceutical manufacturing hubs, where the IP and Indian Pharmacopoeia Reference Substances are already being effectively utilized for ensuring medicine quality, safety, and efficacy. The conclave aimed to strengthen industry awareness, support compliance with pharmacopoeial requirements, and promote consistent adoption of IP standards while providing handholding support to pharmaceutical manufacturers and stakeholders in the state.
The event brought together representatives from pharmaceutical manufacturing units, quality control and quality assurance professionals, regulatory authorities, analytical scientists, and drug testing laboratory personnel to deliberate on recent developments in pharmacopoeial standards and their implementation. The inaugural session featured addresses by Shri Sandeep Jain, Chairman of ADPI, who emphasized the importance of industry-standard-setting body collaboration; Shri Sidharth Sahai Malhotra, Assistant Drugs Controller (India) from CDSCO Dehradun; and Shri Tajber Singh, Drug Controller and State Licensing Authority of Uttarakhand, who highlighted the critical role of pharmacopoeial standards in regulatory compliance and public health protection.
Dr. V. Kalaiselvan, Secretary-cum-Scientific Director of IPC, delivered the Chief Guest address underscoring the pivotal role of IP in establishing scientifically validated quality standards for medicines and supporting India's growing stature as a global pharmaceutical leader. He highlighted key advancements incorporated in IP 2026 and emphasized the importance of industry participation in ensuring effective implementation of pharmacopoeial requirements.
Following the inaugural session, technical deliberations and knowledge-sharing interactions covered key aspects of IP including recent developments in pharmacopoeial standards, reference substances, microbiological quality requirements, quality management systems, analytical investigations, and biological standards. These sessions provided participants with practical insights into the application of IP standards in pharmaceutical manufacturing and quality control. A dedicated interactive session allowed participants to engage directly with IPC scientists for clarifications on technical, regulatory, and implementation-related aspects of IP 2026, reflecting the industry's keen interest in understanding evolving pharmacopoeial requirements and adopting best practices for quality assurance.
The conclave reaffirmed IPC's commitment to fostering greater awareness of pharmacopoeial standards and strengthening collaboration with stakeholders to promote the manufacture of quality-assured medicines. The event concluded with a networking session enabling continued dialogue among regulators, industry representatives, and scientific experts on advancing pharmaceutical quality and compliance in Uttarakhand and across India.